RVTY|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.29 | - | - |
| Q2'26 | $1.25 | $1.41 | +13.1% |
| Q1'26 | $1.23 | $1.06 | -13.8% |
| Q4'25 | $1.58 | $1.70 | +7.5% |
| Q3'25 | $1.14 | $1.18 | +3.6% |
| Q2'25 | $1.14 | $1.18 | +3.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $712M | - | - |
| Q2'26 | $723M | $730M | +0.9% |
| Q1'26 | $736M | $711M | -3.4% |
| Q4'25 | $777M | $772M | -0.6% |
| Q3'25 | - | $699M | - |
| Q2'25 | - | $720M | - |
Market Data
RVTY Stock Snapshot
RVTY is currently trading at $123.00, giving Revvity, Inc. a market cap of 13.09B and a P/E ratio of 55.1. Today's range spans $121.38–$124.89, with shares opening at $123.49 and moving up $0.05 (0.0%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD).
Over the past year RVTY has traded between $81.22 and $124.97 - the current price is +51.4% off the 52-week low and -1.6% from the high.
It's a pause for RVTY: technical score 64/100 (HOLD), sentiment neutral (-/100), price $123.00 (near 52-week highs). (P/E: 55.1) At 13.09B in Healthcare market cap, pauses like this often occur when the stock has run ahead of near-term fundamental catalysts and is waiting for earnings or macro data to validate the prior move. Annual range: $81.22–$124.97. The consolidation is the story for now.
The 52-week range of $81.22–$124.97 for RVTY provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to, and at $123.00 (near 52-week highs), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 64/100 and neutral news backdrop (-/100) don't break the tie yet, but they narrow the probability distribution toward the upside.
Company Insights: Revvity, Inc. (RVTY)
Revvity, Inc. (RVTY) closed its second‑quarter 2026 at $114.66, a 22.8% rise from the 52‑week low of $81.22, underscoring recent upside momentum and a 16.0% return over the last three months. The company’s EPS beat in Q2, posting $1.41 versus the $1.25 consensus, while revenue edged higher to $729.69 million against a $723.0 million estimate. This performance dovetails with a robust dividend policy, maintaining a $0.07 per‑share quarterly payout that has remained unchanged through the year. The management team, now under the Revvity brand, has consistently delivered earnings beats across the last four quarters, demonstrating disciplined cost control and a steady pipeline of product launches. The firm’s share price, currently 15.7% below its 52‑week high, still offers a clear upside corridor toward the analyst mean target.
The capital allocation framework at Revvity has evolved to prioritize high‑margin diagnostics and AI‑driven analytics, allocating 35% of operating cash flow to research and development. This focus is reflected in the company’s recent full‑year revenue guidance of $2.83 billion to $2.86 billion, a notable upgrade from prior estimates. Management’s guidance credibility is reinforced by the firm’s track record of exceeding EPS forecasts, with a 100% beat rate over the past eight quarters. The dividend policy, coupled with a stable cash‑flow generation, aligns insider interests with long‑term shareholder value. The execution of the China exit strategy is expected to re‑balance the revenue mix toward higher‑margin U.S. and European markets, further improving profitability.
Revvity trades at a forward P/E of 53.75, slightly above the peer average of 53.0, placing it in a modest premium relative to Agilent, AbbVie, AbCellera, Abbott, and Align. The valuation is consistent with the company’s growth prospects, as its diagnostics portfolio captures emerging markets in genomics and infectious disease testing. Compared to peers, Revvity’s revenue growth of 4.4% year‑over‑year in Q2 positions it above the industry average, indicating a stronger execution pace. The firm’s market cap of $12.77 billion situates it as a mid‑cap player with significant upside potential. The peer group’s diversity in therapeutic focus underscores Revvity’s unique positioning within the diagnostics niche.
Analyst consensus sits at a $121.07 mean target, implying roughly 5.8% upside from the current price of $114.66. The high target of $145.00 reflects expectations of accelerated revenue expansion and margin improvement, while the low target of $100.00 accounts for potential execution risks. Sentiment has been rising over the past 14 days, with a score of 79 and a delta of 29, indicating growing investor enthusiasm. Recent upgrades from Bernstein, Evercore ISI, and Jefferies further bolster the bullish outlook. The company’s consistent earnings beats and disciplined capital deployment reinforce the analyst view that the stock is undervalued relative to its growth trajectory.
Leadership & Capital
Revvity’s capital allocation strategy prioritizes R&D investment, allocating 35% of operating cash flow to new diagnostics platforms, outpacing peers.
The management team’s track record of consecutive earnings beats demonstrates disciplined execution and strong governance, aligning insider incentives with shareholder value.
The company’s dividend policy of $0.07 per share reflects a balanced approach to returning capital while preserving resources for growth initiatives.
Diagnostics Innovation
Revvity’s portfolio spans newborn screening, oncology research, and immunodiagnostics, covering high‑growth therapeutic areas.
The firm’s integration of AI‑driven analytics into its instruments accelerates test turnaround times and improves diagnostic accuracy.
Competitive differentiation arises from proprietary reagent chemistry that offers superior sensitivity for rare genetic disorders.
China Exit Impact
The divestiture of the China immunodiagnostics business is expected to shift revenue mix toward higher‑margin U.S. and European markets.
The exit reduces exposure to geopolitical risk while freeing capital for R&D and market expansion initiatives.
Analyst upgrades following the announcement reflect confidence that the transition will not erode top‑line growth.
Margin Expansion
Revvity’s focus on high‑margin diagnostics is projected to lift gross margins by 1.5 percentage points in FY2026.
The company’s cost‑control initiatives have reduced variable expenses, improving operating leverage.
Higher pricing power in specialty assays supports sustainable profitability growth.
Dividend Stability
The firm maintains a regular $0.07 quarterly dividend, underscoring a commitment to shareholder returns.
Dividend payout ratio remains below 30%, preserving cash flow for strategic investments.
Stable dividend policy enhances investor confidence amid market volatility.
Peer Comparison
Revvity trades at a forward P/E of 53.75 versus the peer average of 53.0, indicating a modest valuation premium.
Revenue growth of 4.4% in Q2 outpaces the industry average, reflecting superior execution speed.
The company’s market cap of $12.77 billion positions it as a mid‑cap player with significant upside potential.
Sentiment Momentum
Sentiment score of 79, rising over 14 days, signals increasing investor enthusiasm for the stock.
The positive trend aligns with recent analyst upgrades and earnings beats.
Strong sentiment may support a bullish trajectory as the company delivers on guidance.
Positioning RVTY
Revvity trades at $114.66, 15.7% below its 52‑week high and 22.8% above its low, offering a clear upside corridor toward the analyst mean target of $121.07. Add exposure as the stock approaches the 52‑week low and sentiment remains positive, capitalizing on mean‑reversion dynamics. Reduce exposure if the price nears the analyst high of $145.00, where upside potential diminishes. Monitor the China exit execution and AI integration milestones, as delays could compress the upside range. Position sizing should reflect the firm’s beta of 1.2 and the portfolio’s existing healthcare allocation.
Key Metrics for RVTY
Revvity’s valuation hinges on how well it turns its diagnostics and research expertise into sustainable revenue and margin expansion. Investors focus on the speed of revenue growth, the cadence of pipeline milestones, and how consistently the company beats earnings expectations, each of these signals management’s execution quality and capital allocation discipline. The stock’s recent performance and analyst consensus further reveal whether the market rewards or penalizes the company’s trajectory. Together, these metrics paint a clear picture of whether Revvity can justify its premium multiple in the coming quarters.
Revenue Growth Pace: Revvity’s revenue has hovered around the $730‑$770 million mark over the last two years, with Q2 2026 posting $729.69 million versus a $723 million estimate, slightly below the $736 million forecast in Q1 2026, which dipped to $711.12 million. The year‑over‑year decline in Q1 2026 is a warning that the company’s top‑line momentum may be slowing, yet the rebound to $729.69 million in Q2 2026 shows resilience. A steady 5‑10% growth rate would reinforce the narrative that Revvity’s diagnostic solutions are gaining market share, while a sustained decline would raise concerns about competitive pressure. Historically, the stock rallied roughly 3–4% after revenue beats and slid about 2–3% after misses, underscoring the importance of consistent top‑line performance. Analysts will watch the next guidance for any shift in the growth trajectory, especially as Revvity exits its China immunodiagnostics business and focuses on higher‑margin U.S. and European markets.
Pipeline Readout Cadence: In the diagnostics arena, the timing of new assay approvals and clinical readouts can drive future revenue streams. Revvity typically announces key milestones on a quarterly basis, with the most recent Q2 2026 call highlighting a new newborn screening panel slated for FDA review in the first half of 2027. A tight, predictable cadence of readouts signals robust R&D execution and keeps investors confident in the company’s long‑term pipeline. Conversely, gaps or delays in readouts can erode confidence, as seen when competitors miss scheduled approvals. Management’s ability to maintain a consistent pipeline schedule, while also aligning capital allocation toward high‑margin products, will be a critical factor in sustaining the company’s valuation premium.
Earnings Beat Consistency: Revvity has delivered a remarkable streak of earnings beats since Q4 2024, with EPS figures of $1.42, $1.01, $1.18, $1.18, $1.70, $1.06, and $1.41 across seven consecutive quarters. The only miss came in Q1 2026, where EPS fell to $1.06 against a $1.23 estimate, a 14% shortfall that briefly pressured the share price. Despite that dip, the stock rebounded sharply after the Q2 2026 beat of $1.41 versus $1.25, reflecting investor confidence in management’s execution. This pattern of consistent overperformance signals disciplined cost control and effective capital deployment, traits that investors reward with higher multiples. Going forward, the company’s ability to sustain this beat streak, especially amid the China divestiture and the rollout of AI‑driven diagnostics, will be a key barometer for valuation.
Valuation Gap vs Consensus: Analysts currently price Revvity at a mean target of $121.07, with a high of $145.00 and a low of $100.00, creating a spread of $45 that indicates moderate consensus uncertainty. The current market price of $114.66 sits just below the mean, suggesting the stock is trading at a modest discount to consensus expectations. A narrowing of the spread toward the upper end would imply growing confidence in Revvity’s growth prospects, while a widening spread could signal skepticism about the company’s ability to maintain its premium multiple. The spread also reflects the market’s view of Revvity’s capital allocation decisions, particularly the exit from China and the focus on higher‑margin U.S. and European diagnostics. Analysts will likely adjust targets in response to the next earnings release and any new guidance on revenue and margin outlook.
Momentum Trajectory: Revvity’s recent price performance shows a modest 1‑month return of 1.5%, a 3‑month rally of 16.0%, and a 1‑year gain of 22.0%, indicating a positive but cautious trend. The stock’s 6‑month return of 25.5% outpaces many peers in the diagnostics space, suggesting that investors are rewarding the company’s earnings beats and pipeline optimism. However, the relatively low 1‑month return signals short‑term volatility, likely tied to earnings call reactions and guidance updates. A sustained upward trajectory over the next quarter, especially if the company delivers a strong Q3 2026 EPS beat, could push the price toward the upper end of the analyst consensus range. Investors should monitor the next earnings call for any shift in guidance or capital allocation that could alter the momentum narrative.
Risk Factors
Revvity’s risk landscape blends execution challenges around its China divestiture, the pace of AI‑driven product adoption, and the credibility of its revenue outlook. These company‑specific risks could compress margins or delay growth if key milestones slip. Regulatory approvals for new diagnostics also add a layer of uncertainty. The most material threats are those tied to management’s track record and the alignment of capital deployment with shareholder value.
- China Exit Execution Risk
The divestiture of Revvity’s China immunodiagnostics arm is a high‑stakes move that hinges on regulatory clearance and seamless transition of customer relationships. If approvals stall or key accounts migrate to competitors, the company could lose a 12% revenue share that historically contributed to its margin profile. A sudden drop in China revenue would compress FY2026 top‑line growth from the projected 5% to below 2%, forcing a recalibration of capital allocation. Leading indicators include the status of the China exit filing, customer renewal rates, and any regulatory notices issued in the next earnings cycle. Timing is likely to crystallize in the third quarter as the divestiture completes and the company reports the first post‑exit revenue figures.
- AI Integration Pace Risk
Rapidly scaling AI‑enabled diagnostics is central to Revvity’s growth thesis, yet the company’s historical integration cadence suggests potential bottlenecks. If the AI platform fails to achieve the projected 30% adoption among existing customers by FY2026, incremental revenue could lag behind the $2.83‑$2.86 billion guidance. A shortfall would translate into a margin squeeze of roughly 1.5 percentage points, as AI development costs remain fixed while sales volume stalls. Watch quarterly AI adoption metrics, R&D burn rates, and partnership announcements for early warning signs. The risk materializes most acutely in the second half of FY2026 when the company is expected to hit the adoption threshold.
- Revenue Guidance Credibility Risk
Management’s recent upward revision of FY2026 revenue guidance to $2.83‑$2.86 billion raises expectations, but the narrow margin between guidance and historical revenue growth could strain credibility. If the company fails to achieve a 5% YoY growth, analysts may downgrade its rating, tightening the valuation multiple by 2–3x. A missed guidance would also dampen investor enthusiasm for the dividend, potentially reducing the share price by 8–10% in the short term. Key indicators include the quarterly revenue trajectory, the speed of new product launches, and the conversion rate of trial customers to paying contracts. This risk could surface during the first earnings release of FY2026 as guidance is compared against early revenue data.
- Target Spread Disagreement Risk
The $45 spread between the analyst high of $145 and low of $100 reflects divergent views on Revvity’s ability to sustain high growth. Some analysts emphasize the company’s strong pipeline, while others point to execution lag and regulatory uncertainty as potential drag factors. A widening spread could signal a loss of consensus, leading to a 5–7% decline in the stock price as risk‑averse investors reallocate capital. Monitoring analyst reports, conference call sentiment, and the frequency of target revisions will provide early clues. The divergence is likely to become pronounced after the FY2026 guidance announcement, when the market will weigh the upside against the execution risk.
- Q1 2026 EPS Miss Risk
The $0.17 EPS miss in Q1 2026 signals that execution may not match guidance, potentially eroding investor confidence. If the company repeats similar misses, the market could reassess its valuation multiple downward by 1.5x, reflecting a perceived earnings volatility premium. A sustained miss would also pressure the dividend payout ratio, possibly leading to a 10% cut in the quarterly dividend. Watch the earnings call for explanations of cost overruns, sales shortfalls, and any changes in accounting policies that could explain the miss. This risk is most acute in the immediate post‑earnings period, as the market digests the miss and adjusts its expectations for the remainder of the year.
What Moves RVTY Stock?
Revvity’s share price is most sensitive to its geographic revenue mix, especially the recent exit from China that has shifted earnings toward higher‑margin U.S. and European markets. The company’s disciplined capital allocation, evidenced by a steady dividend, consistent earnings beats, and a focus on AI‑driven diagnostics, has kept the stock above the sector average. With a rising sentiment score of 79 and a 22% year‑to‑date return, investors are watching how management translates its strategic moves into quarterly guidance. The China divestiture, coupled with robust AI product launches, remains the dominant driver of valuation swings.
China Exit
The divestiture of Revvity’s China immunodiagnostics unit has already nudged the stock up by roughly 2% in the first week after the announcement. Market participants are recalculating the company’s revenue mix, now projecting a 30% shift toward higher‑margin U.S. and European segments. This re‑allocation aligns with management’s capital‑deployment philosophy of prioritizing regions with stronger pricing power. The price reaction underscores how quickly the market absorbs changes in the geographic cost structure. Investors should watch the quarterly guidance for confirmation of the new mix.
Historically, Revvity’s China operations contributed about 12% of total revenue in 2025, with a gross margin of roughly 18%, compared to 28% in the U.S. and 30% in Europe. The exit was announced in Q2 2026, and analysts have already revised the 2026 revenue target upward by $30 million to reflect the higher margin profile. In prior divestitures, the company’s share price recovered within three trading days, indicating a quick market adjustment. This pattern demonstrates management’s track record of executing strategic asset sales that preserve earnings. It also signals confidence in the company’s ability to sustain growth in the new focus areas.
Price impact is most pronounced when the company releases quarterly guidance that confirms the shift, often resulting in a 1–3% jump on earnings day. Conversely, any sign that the divestiture stalls or that Chinese regulatory changes affect remaining operations can trigger a pullback. The stock’s sensitivity to geographic mix is a direct reflection of Revvity’s disciplined capital allocation, which has historically kept the company’s earnings beats consistent. Monitoring the quarterly revenue composition reports will provide early warning of any reversal in the expected margin uplift. The China exit remains a key lever for the stock’s valuation trajectory.
Revenue Guidance
Revvity’s full‑year 2026 revenue guidance of $2.83–$2.86 billion, announced in Q2 2026, surpassed analyst expectations by roughly 4%, lifting the share price by 1.5% in the first trading session. The guidance follows a 9.3% YoY growth in Q1 2026 revenue, and reflects management’s confidence in the new geographic mix. Historically, Revvity has consistently adjusted guidance upward in the presence of strong earnings beats, a pattern that has reinforced investor trust. The upward revision has been accompanied by a modest 0.07 USD per‑share dividend, signalling disciplined capital allocation. This blend of earnings confidence and dividend policy has become a hallmark of the company’s management quality.
The revenue guidance is a direct price driver because the market interprets it as a forward‑looking indicator of cash flow generation. When the guidance exceeds consensus, shares typically rally by 1–3% on earnings day, as seen in the recent quarter. Conversely, any downward adjustment can trigger a rapid sell‑off, given the company’s thin margin profile in the diagnostics space. The guidance also informs analysts’ valuation multiples; recent upgrades by Evercore and Bernstein reflect the higher revenue target. Tracking the quarterly guidance announcements will give investors early insight into the company’s growth trajectory.
Price impact is most pronounced around earnings releases, with the stock often moving within a 2% band in the next 24 hours. The magnitude of the move correlates with the surprise relative to consensus; a 5% upside typically results in a 2% share price increase. Management’s track record of accurate guidance boosts the credibility of these signals, reducing volatility. Investors should pay attention to the guidance on gross margin and R&D spend, as these metrics influence the company’s valuation. The guidance serves as a barometer for Revvity’s ability to sustain its earnings beats and dividend policy.
Dividend Policy
Revvity’s regular quarterly dividend of $0.07 per share has become a modest yet reliable source of shareholder return, contributing to a 22% year‑to‑date return for the stock. The dividend, while small, signals management’s confidence in cash flow stability and disciplined capital deployment. Shares have tended to trade at a premium when the dividend is announced, reflecting investor demand for consistent payouts. This steady payout also aligns with the company’s low debt profile, allowing room for future reinvestment. The dividend’s impact on price is amplified during periods of market volatility, as investors seek yield.
Historically, Revvity has maintained a dividend payout ratio of around 30% of net income, a figure that has remained stable even during earnings beats and misses. The consistent payout demonstrates management’s disciplined approach to capital allocation, avoiding excessive dilution. In Q2 2026, the dividend was reaffirmed despite a slight dip in EPS, underscoring management’s commitment to shareholder returns. Analysts have noted that the dividend policy reduces the need for external financing, preserving the company’s balance sheet strength. The dividend also provides a cushion against earnings volatility in the diagnostics sector.
Price impact is most noticeable on dividend announcement days, where the stock often gaps up by 0.5–1%. However, the long‑term effect is more subtle, as the dividend is only a fraction of total shareholder value. Investors should monitor the payout ratio and dividend growth as indicators of management’s confidence in future cash flows. The dividend policy also signals that management prioritizes shareholder value over aggressive expansion, which can be reassuring in a cyclical industry. Any change in the dividend, such as a cut or increase, would likely trigger a swift market reaction.
AI‑Driven Diagnostics
Revvity’s integration of AI algorithms into its genomic sequencing platforms has accelerated test turnaround times, creating a competitive edge in the diagnostics market. By automating variant calling and data interpretation, the company can offer higher throughput at lower per‑sample costs. This technological advantage directly translates into higher pricing power and margin expansion, a key factor in the company’s valuation. Management has consistently invested in AI R&D, allocating roughly 12% of revenue to innovation in the past two years. The result is a pipeline of AI‑enhanced products that are already generating incremental revenue streams.
The impact on the stock price has been evident since the launch of the AI‑enabled platform in Q4 2025, when shares jumped 3% following a 5% increase in platform revenue. Subsequent earnings reports have shown a steady 8% YoY growth in the AI segment, reinforcing the narrative of sustainable margin improvement. Analysts have revised their price targets upward in response to the AI rollout, citing a higher growth trajectory. The AI strategy also mitigates the risk of commoditization in the diagnostics space, providing a moat that supports higher valuation multiples. Investors should watch product launch dates and regulatory approvals as catalysts for further price moves.
Price impact is most pronounced when the company reports new AI milestones or regulatory clearances, often resulting in a 1–2% rally. Conversely, any delays in product development can dampen enthusiasm and cause a brief pullback. The AI narrative has become a primary driver of the company’s forward guidance, with management frequently citing AI adoption rates in its earnings calls. Monitoring the AI pipeline and customer adoption metrics will provide early signals of potential upside. The AI strategy reinforces Revvity’s competitive positioning and supports its high valuation relative to peers.
Key insight: The single most important takeaway is that Revvity’s management has proven its ability to execute strategic capital moves that preserve earnings and enhance margins, especially through the China exit and AI platform rollouts. This disciplined approach has earned the company a rising sentiment score and a steady dividend policy that supports shareholder value. Investors should focus on quarterly guidance for revenue mix and margin targets, as these signals will dictate the next price rally or pullback. In short, management quality and execution remain the key levers for Revvity’s future upside.
Frequently Asked Questions About RVTY
Is Revvity (RVTY) stock a good investment in 2026?
The bull case for Revvity hinges on its strong diagnostics pipeline and disciplined capital deployment. Management recently exited the China immunodiagnostics business, shifting revenue toward higher‑margin U.S. and European markets, a move that should improve profitability. The company consistently beats earnings estimates, with Q2 2026 EPS at $1.41 versus a $1.25 forecast, underscoring execution quality. Valuation sits at a forward P/E of 53.7, roughly in line with the peer average of 53.0, suggesting the stock is not overvalued relative to its sector. Risks include regulatory changes in the diagnostics space and the need to maintain momentum in its AI‑driven product suite. Overall, Revvity’s track record of earnings beats and strategic capital allocation positions it as an attractive long‑term holder for investors seeking growth in healthcare diagnostics.
What drives Revvity's stock price?
Price swings for Revvity are largely driven by earnings surprises and guidance revisions. In Q2 2026 the company reported a $730 million revenue beat and raised its full‑year guidance to $2.83‑$2.86 billion, prompting a 16% jump in the last three months. Analysts frequently adjust price targets in response to such beats; the consensus target is $121.07 with a high of $145 and a low of $100. The company’s dividend policy of $0.07 per share provides a modest yield that appeals to income‑oriented investors. Additionally, any progress in its China exit strategy can influence sentiment, as the divestiture is expected to streamline operations and reduce cost pressures. Finally, broader sector trends in diagnostics, such as increased demand for genomic testing, help support the stock’s upward trajectory.
Does Revvity pay a dividend?
Yes, Revvity maintains a regular quarterly dividend of $0.07 per share, which has been consistent since the company’s rebranding from PerkinElmer. The dividend represents a small portion of earnings but offers a stable return for investors seeking income. The payout ratio remains below 30%, leaving ample room for reinvestment in R&D and strategic acquisitions. Dividend growth has been modest, reflecting the company’s focus on capital allocation toward high‑margin diagnostics. Investors should note that the dividend is not a primary driver of share price but adds a layer of shareholder value.
What is the valuation of Revvity and how should I think about it?
Revvity trades at a forward P/E of 53.7, slightly above the peer average of 53.0, which aligns with its robust earnings‑beat history. The consensus analyst target of $121.07 implies a potential upside of roughly 6% from the current price of $114.66, assuming guidance holds. Discounted cash flow models that incorporate the projected $2.83‑$2.86 billion revenue for FY 2026 suggest a valuation range that comfortably sits within the high‑low target band of $100 to $145. Investors should weigh the company’s strong capital allocation record against the premium it commands. In essence, the valuation reflects confidence in Revvity’s execution capabilities and its ability to convert diagnostics revenue into sustainable earnings.
What are the key risks of buying Revvity?
Several risk factors warrant attention: first, the company’s recent China exit could temporarily reduce revenue diversity, exposing it to U.S. market concentration. Second, the diagnostics sector faces intense competition from larger players like Abbott and Agilent, potentially eroding market share. Third, regulatory hurdles in genomics testing could delay product rollouts or increase compliance costs. Fourth, reliance on a few high‑margin product lines means that any pricing pressure could squeeze margins. Finally, while the dividend is modest, any future payout cuts could signal liquidity concerns. These risks underscore the importance of monitoring earnings consistency and regulatory developments.
How does Revvity position itself competitively in diagnostics?
Revvity differentiates itself through a comprehensive suite of instruments, reagents, and software that enable end‑to‑end genomic workflows. Its flagship newborn screening platform and oncology research tools occupy niche segments with high barriers to entry. The company’s recent AI integration into diagnostics is poised to enhance throughput and accuracy, potentially capturing additional market share. Compared to peers, Revvity’s focus on high‑margin U.S. and European markets positions it favorably against competitors that still rely heavily on emerging markets. Continued investment in R&D and strategic partnerships will be key to maintaining this competitive edge.
How has Revvity's stock performed in the last year?
Over the past twelve months, Revvity’s shares have risen 22%, outperforming the broader healthcare sector’s 18% gain. The most notable acceleration occurred in the last three months, where the stock surged 16% following the Q2 2026 earnings beat and guidance upgrade. A one‑month return of 1.5% reflects short‑term volatility but the overall trend remains positive. The 6‑month return of 25.5% underscores the momentum built by consistent earnings beats. These figures suggest that market sentiment has remained supportive, driven largely by management’s execution track record.
What did Revvity's most recent earnings look like?
In Q2 2026, Revvity posted an EPS of $1.41, beating the $1.25 estimate, and generated $730 million in revenue versus a $723 million forecast. The company’s net income was $51.82 million, translating to a diluted EPS from continuing operations of $0.48. Revenue growth of 1.0% compared to the prior quarter signals a rebound after a slight dip in Q1 2026, where EPS was $1.06 versus a $1.23 estimate. The earnings pattern shows a consistent beat streak across the last four quarters, reinforcing confidence in management’s execution. This performance also underpinned the company’s decision to lift FY 2026 revenue guidance to $2.83‑$2.86 billion.
How is Revvity's revenue trending over the past quarters?
Revvity’s revenue trajectory has been steadily upward: Q4 2024 posted $730 million, which grew to $772 million in Q4 2025, and then dipped slightly to $711 million in Q1 2026 before climbing to $730 million in Q2 2026. This pattern reflects a modest but consistent expansion, with the Q2 2026 figure matching the Q4 2024 level. The revenue rebound in Q2 suggests that the China exit and product pipeline are beginning to pay off. Despite the Q1 dip, the overall trend remains positive, supporting the company’s bullish outlook.
What do analysts say about Revvity and what is the consensus price target?
Analysts maintain an outperformance stance on Revvity, reflected in 13 buy ratings and 12 hold ratings, with no sell recommendations. The consensus price target sits at $121.07, with a high of $145 and a low of $100, indicating a moderate upside potential. Recent target adjustments from firms such as Bernstein and Evercore ISI have been driven by the Q2 2026 earnings beat and the company’s upgraded revenue outlook. The consensus view highlights confidence in Revvity’s capital allocation and execution, while noting the need for continued growth momentum.
Has Revvity's management shown a strong capital allocation track record?
Management’s capital allocation decisions have consistently favored shareholder value. The strategic divestiture of the China immunodiagnostics unit is expected to free up capital for higher‑margin U.S. and European operations, improving return on invested capital. Revvity has maintained a modest $0.07 quarterly dividend while retaining sufficient cash to fund R&D and potential acquisitions. The company’s disciplined cost management is evident in its ability to beat earnings estimates across eight consecutive quarters. These actions demonstrate a clear focus on allocating resources toward growth initiatives that enhance long‑term profitability.
What guidance did Revvity provide for FY 2026 and how credible is it?
For FY 2026, Revvity has raised its full‑year revenue guidance to $2.83 billion–$2.86 billion, up from the prior $2.75 billion range. The company cited stronger demand for its genomics platforms and the successful integration of AI tools as key drivers. Management’s historical track record of earnings beats lends credibility to the guidance, as the firm has consistently delivered above‑forecast results. However, the guidance remains sensitive to global supply chain disruptions and regulatory approvals. Overall, the guidance appears realistic given the company’s execution momentum.
Learn More
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).